Avasimibe Pfizer.
作者信息
Burnett John R, Huff Murray W
机构信息
Department of Core Clinical Pathology & Biochemistry, Division of Laboratory Medicine, Royal Perth Hospital, Wellington Street, Perth, WA 6847, Australia.
出版信息
Curr Opin Investig Drugs. 2002 Sep;3(9):1328-33.
PMID:12498009
Abstract
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
摘要
Zotero 插件